Adriana PC Barrichello, Allan AL Pereira, Maria Dirlei FS Begnami, Marcus Vinicius Grigolon, Eduarda SC Oliveira, and Gustavo S Fernandes
Introduction: Pancreatic Acinar Cell Carcinoma (PACC) is a rare subgroup of pancreatic neoplasms that has a better prognosis compared to Pancreatic Ductal Adenocarcinoma (PDAC). The more indolent evolution of the PACC makes surgical resection the standard treatment for localized disease. In metastatic disease, treatment is not well established. BRAF mutations have been detected in up to 13% of PACC, however, treatment with BRAF and/or MEK inhibitors has not yet been studied.
Case report: We present the case of a 73-year-old man, who has the diagnosis of BRAF-mutated metastatic PACC refractory to chemotherapy regimens. He underwent the combination of dabrafenib (selective BRAF inhibitor) and trametinib (selective MEK inhibitor) and had a partial response after 2 and 6 months from initiation of treatment.
Discussion: This case suggests the hypothesis that the block of the RASâ€
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu